K-PAX, the comprehensive multivitamin/antioxidant formula for immune support, is now the subject of a randomized clinical trial in Canada. The sponsors of the Canadian trial are the Canadian HIV Trials Network and the Ontario HIV Treatment Network (OHTN). This is a high-quality scientific study, that is, it’s a double-blind, placebo-controlled randomized clinical trial–the same kind of investigation required by the FDA before approval of drugs.
The Canadian K-PAX trial is enrolling antiviral-naive HIV-infected patients, and seeks to test whether K-PAX can provide useful support for the CD4 counts of HIV(+) individuals who have not yet begun taking anti-retroviral medications. (Patients starting the study will have CD4 counts between 350 – 800.) Half the group will be randomly chosen to receive K-PAX, while the other half will receive a low-dosage type multivitamin like those sold over the counter in drugstores.
We welcome this follow-up study on the K-PAX formula. The first study, which led to wide release of the K-PAX formula, was published in 2006 and did show a significant increase in CD4 counts among those taking it, whereas other participants had no increase or even some decline. We should also mention that our predecessor organization, DAAIR, was suggesting multivitamin/antioxidant protocols for people with HIV/AIDS back in the 1990s, even before anti-retroviral therapy became generally available.
In 2006, meanwhile, NYBC developed a close equivalent of the K-PAX formula using components from its product list. This allowed the purchasing co-op to offer its MAC-Pack (Multivitamin-Antioxidant-Combination Pack) for approximately half the price of the K-PAX, a useful alternative especially for those living in localities where K-PAX was not covered by ADAP or other insurance. See www.newyorkbuyersclub.org for more details.